GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » EBITDA Margin %

Integra Lifesciences Holdings (Integra Lifesciences Holdings) EBITDA Margin % : 18.54% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Integra Lifesciences Holdings's EBITDA for the three months ended in Dec. 2023 was $74 Mil. Integra Lifesciences Holdings's Revenue for the three months ended in Dec. 2023 was $397 Mil. Therefore, Integra Lifesciences Holdings's EBITDA margin for the quarter that ended in Dec. 2023 was 18.54%.


Integra Lifesciences Holdings EBITDA Margin % Historical Data

The historical data trend for Integra Lifesciences Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings EBITDA Margin % Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.73 20.49 24.95 24.51 16.60

Integra Lifesciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.78 19.17 12.36 16.27 18.54

Competitive Comparison of Integra Lifesciences Holdings's EBITDA Margin %

For the Medical Devices subindustry, Integra Lifesciences Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's EBITDA Margin % falls into.



Integra Lifesciences Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Integra Lifesciences Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=255.958/1541.573
=16.60 %

Integra Lifesciences Holdings's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=73.594/397.039
=18.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings  (NAS:IART) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Integra Lifesciences Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines

From GuruFocus